Adamis Pharmaceuticals (ADMP) Prices $6.7M Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- FedEx pilots ratify new collective bargaining agreement
- The real reason Meta shares are surging has nothing to do with its new AI model
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering
February 21, 2020 9:15 AM ESTSAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (Adamis or the Company) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $6.7 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. Â The combined purchase price for one share of common stock and 0.75 warrants will be $0.58.
Under the terms of the purchase agreement, Adamis has agreed to sell 11,600,000 shares of its common stock. Â In a concurrent private placement,... More
